Nephrogenic Systemic Fibrosis

被引：24

作者：

Weinreb, Jeffrey C. ^{[1
,2
]}

Kuo, Philip H. ^{[3
,4
]}

机构：

[1] Yale Univ, Sch Med, Dept Diagnost Radiol, New Haven, CT 06520 USA

[2] Yale New Haven Med Ctr, Body Imaging & MRI, New Haven, CT 06520 USA

[3] Univ Arizona, Dept Med, Hematol Oncol Sect, Tucson, AZ 85724 USA

[4] So Arizona Vet Adm Hosp, Dept Radiol, Tucson, AZ 85724 USA

来源：

MAGNETIC RESONANCE IMAGING CLINICS OF NORTH AMERICA | 2009年 / 17卷 / 01期

关键词：

Gadolinium; Nephrogenic systemic fibrosis; Gadolinium-based contrast agent; MR imaging; MR contrast agents; Gadolinium chelates; GADOPENTETATE DIMEGLUMINE; GADOBENATE DIMEGLUMINE; MR-ANGIOGRAPHY; GADOLINIUM; RISK; DERMOPATHY;

D O I：

10.1016/j.mric.2009.01.003

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

There seems to be an association between exposure to intravenous gadolinium-based contrast agents (GBCAs) and nephrogenic systemic fibrosis (NSF), a debilitating and sometimes fatal disease. This article addresses the relationship between GBCAs and NSF and answers some common questions. The policy deployed at Yale-New Haven Hospital for prevention of NSF and screening for patients at risk is delineated and discussed along with recommendations by the Food and Drug Administration.

引用

页码：159 / +

页数：10

共 35 条

[1]

[Anonymous], ACR Manual on Contrast Media 2021

[2] Gadodiamide-associated nephrogenic systemic fibrosis: Why radiologists should be concerned [J].